NYMOX Provides Current Updates, The Canadian Business Journal

IRVINE, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) — Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide an update on its business developments.

We have been in contact and meeting with the FDA over the past few months. The agency has provided us with very useful feedback. FDA has specified additional information required for NDA resubmission. We are preparing the requested documentation for resubmission of the requested data and further communication with FDA for additional guidance.

The company plans to file a marketing application for Fexapotide in Europe in the fourth quarter of this year and will provide further information as the time for the Fexapotide application approaches in the near future.

Nymox CEO Paul Averback said: Additionally, the agency has consistently provided helpful feedback. The company and its extensive team are committed to making this amazing new treatment available to the millions of men who need a safer, more effective option to manage their cumbersome and painful lower urinary tract. We are doing everything in our power to do so. Symptoms of BPH. “

Fexapotide is an office injection that is administered in minutes without the need for anesthesia or analgesia. Overall, the drug has been tested in clinical trials on more than 1,750 of his BPH patients and has given her more than 1,600 injections, including more than 1,200 of his Fexapotide doses. . Fexapotide has shown significant long-term improvement and an excellent safety profile without the side effects typically associated with her existing BPH treatment.

Contact us for more information [email protected] Also 800-936-9669.

Forward-Looking Statements

To the extent statements contained in this press release are not statements of historical facts regarding Nymox, they are forward-looking statements that reflect management’s current beliefs and expectations made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This is a forward-looking statement. It includes statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer, and the estimated timing of further development of Fexapotide. Such forward-looking statements involve substantial risks and risks that our clinical development programs, future results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements. Contains uncertainty. Such risks and uncertainties include, among other things, the regulatory approval process, the timing of Nymox’s regulatory submissions, Nymox’s substantial reliance on Fexapotide, Nymox’s commercialization plans and commitments, and Includes uncertainties inherent in the clinical drug development process, including other issues that may impact manufacturing. Availability or Commercial Potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward-looking statements. Details of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, and the risks generally associated with Nymox’s business, are filed with U.S. Securities. See Nymox current and future reports. Annual Report on Form 20-F for the year ended December 31, 2021, and the Securities and Exchange Commission, including its quarterly reports.

for further away information contact:
Randall Lanham
1-800-93NYMOX
www.nymox.com

CBJ Newsmaker